摘要
目的:探讨复方苦参注射液联合吉西他滨和顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效及其影响。方法:80例晚期NSCLC患者随机分为GP组(吉西他滨加顺铂)和GKP组(吉西他滨加顺铂加复方苦参注射液)。化疗后对患者的疗效及不良反应进行评价。结果:治疗后GP组总有效率为32.5%,GKP组为57.5%(P<0.05)。GP组1年和2年生存率分别为30.0%和18.0%,GKP组35.0%和20.0%。主要的毒性是3级或4级骨髓抑制,治疗后白细胞、中性粒细胞和血小板的减少率2组之间有显著差异(P<0.05)。结论:在疗效方面GKP组优于GP组,同时GKP方案的不良反应减少率较GP方案更显著,因此GKP方案值得临床推广使用。
Objective：To explore the curative effect and other influences of Fufang Kushen Zhusheye combined regimens containing gemcitabine and cisplatin for advanced non-small cell lung cancer（NSCLC）.Methods：A total of 80 advanced NSCLC patients were divided randomly into two groups：GP group [（gemcitabine,G） plus（cisplatin,P）] and GKP group [（GP） plus（Fufang Kushen Zhusheye,K）].The efficacies and side effects were analyzed and compared after chemotherapy.Results： After treatment,the overall response rate was 32.5% in GP group and 57.5% in GKP group（P0.05）.The 1-and 2-year survival rates were 30.0.% and 18.0% in GP group,and 35.0% and 20.0% in GKP group.The major toxicity was grade 3 or 4 myelosuppression,the reducing rates of leucopenia,neutropenia and thrombocytopenia had significantly difference（P0.05） in both groups after treatment.Conclusions： The GKP group was superior to GP group in curative efficacy,but side effects were more remarkably reduction in the GKP regimen than in GP regimens,therefore,and the GKP regimen is worth of recommendation to clinical use.
出处
《中国临床医学》
2011年第4期489-491,共3页
Chinese Journal of Clinical Medicine
关键词
非小细胞肺癌
复方苦参注射液
顺铂
吉西他滨
Non-small cells lung cancer
Fufang kushen zhusheye
Cisplatin
Gemcitabine
